

# Muzaffar H Qazilbash

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8558330/publications.pdf>

Version: 2024-02-01

259  
papers

5,834  
citations

109321

35  
h-index

95266

68  
g-index

261  
all docs

261  
docs citations

261  
times ranked

5465  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2023, 98, 140-147.	4.1	12
2	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	1.4	9
3	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	1.3	8
4	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	2.4	19
5	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	2.4	4
6	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
7	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	1.2	9
8	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	2.4	2
9	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 1277-1284.	7.0	4
10	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	5.2	17
11	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> , 2022, 12, 27.	6.2	19
12	Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	1.0	0
13	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	1.2	1
14	Financial toxicity in hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, 74.	6.2	22
15	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	2.4	7
16	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	1.2	6
17	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8057-8057.	1.6	0
18	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20024-e20024.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Phase II study of umbilical cord bloodâ€‘derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8009-8009.	1.6	2
20	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021, 144, 74-81.	1.4	2
21	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	1.2	13
22	POEMS syndrome: A multisystem clonal disorder. <i>European Journal of Haematology</i> , 2021, 106, 14-18.	2.2	11
23	Gene expression profiling predicts relapseâ€‘free and overall survival in newly diagnosed myeloma patients treated with novel therapies. <i>British Journal of Haematology</i> , 2021, 192, e115-e120.	2.5	3
24	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	2.4	5
25	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 272.e1-272.e5.	1.2	12
26	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 243.e1-243.e6.	1.2	1
27	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021, 56, 2005-2012.	2.4	11
28	Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8022-8022.	1.6	1
29	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	1.2	3
30	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	1.2	18
31	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	1.4	31
32	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	1.2	6
33	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	1.2	14
34	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	3.5	13
35	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	1.6	32
36	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. <i>Cancer</i> , 2021, 127, 4233-4239.	4.1	8

#	ARTICLE	IF	CITATIONS
37	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	7.0	3
38	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2021, 96, E455-E457.	4.1	3
39	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1003.e1-1003.e13.	1.2	10
40	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. <i>Bone Marrow Transplantation</i> , 2021, 56, 1316-1324.	2.4	18
41	Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021, 13, 5888.	3.7	15
42	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1779-1779.	1.4	0
43	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. <i>Blood</i> , 2021, 138, 482-482.	1.4	2
44	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 197-203.	2.0	16
45	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
46	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
47	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
48	Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 420-426.	2.2	11
49	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
50	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	5.2	11
51	Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3101-3111.	1.3	3
52	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
53	Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation. <i>Annals of Translational Medicine</i> , 2020, 8, 509-509.	1.7	0
54	Haploidentical transplants for patients with relapse after the first allograft. <i>American Journal of Hematology</i> , 2020, 95, 1187.	4.1	6

#	ARTICLE	IF	CITATIONS
55	Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. <i>Experimental Hematology</i> , 2020, 81, 32-41.	0.4	8
56	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
57	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	5.2	7
58	Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 46-47.	1.4	5
59	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8506-8506.	1.6	63
60	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. <i>Blood</i> , 2020, 136, 11-13.	1.4	0
61	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
62	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
63	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 22-22.	1.4	0
64	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
65	Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	0
66	Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
67	Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
68	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
69	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
70	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
71	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
72	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	1.4	0

#	ARTICLE	IF	CITATIONS
73	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. <i>Blood</i> , 2020, 136, 9-10.	1.4	1
74	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
75	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 24-25.	1.4	1
76	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	1.3	15
77	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	1.3	11
78	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	1.8	6
79	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019, 67, 51-55.	1.8	13
80	The therapeutic role of natural killer cells in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e49.	0.9	2
81	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019, 104, e555-e557.	3.5	6
82	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	4.6	68
83	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	1.6	184
84	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
85	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	7.0	10
86	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. <i>Bone Marrow Transplantation</i> , 2019, 54, 1089-1093.	2.4	20
87	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
88	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 601-606.	2.4	24
89	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	4.1	5
90	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 505-514.	2.0	15

#	ARTICLE	IF	CITATIONS
91	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. <i>Blood</i> , 2019, 134, 2723-2723.	1.4	14
92	Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival. <i>Journal of Clinical Oncology</i> , 2019, 37, e19535-e19535.	1.6	0
93	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. <i>Blood</i> , 2019, 134, 257-257.	1.4	1
94	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. <i>Blood</i> , 2019, 134, 4598-4598.	1.4	0
95	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
96	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. <i>Blood</i> , 2018, 131, 1248-1257.	1.4	16
97	Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. <i>Bone Marrow Transplantation</i> , 2018, 53, 315-325.	2.4	9
98	Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 815-819.	2.0	13
99	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018, 27, 979-985.	3.1	5
100	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	1.3	4
101	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	4.6	23
102	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 94, E72-E74.	4.1	4
103	New Cancer Therapies: Implications for the Perioperative Period. <i>Current Anesthesiology Reports</i> , 2018, 8, 362-367.	2.0	4
104	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2197-2203.	2.0	22
105	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	1.4	0
106	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 581-587.	2.0	14
107	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	1.6	6
108	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1059-1063.	2.0	3

#	ARTICLE	IF	CITATIONS
109	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	2.5	12
110	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	4.1	11
111	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	4.6	19
112	Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 126-135.	2.3	11
113	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017, 177, 567-577.	2.5	7
114	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	2.5	158
115	Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 388-392.	2.2	12
116	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
117	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	4.6	132
118	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 532-535.	2.2	18
119	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
120	PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. <i>Leukemia</i> , 2017, 31, 697-704.	7.2	90
121	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	2.2	6
122	Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?. <i>World Journal of Transplantation</i> , 2017, 7, 250-259.	1.6	11
123	Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor hematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 444-455.	2.5	61
124	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	4.1	48
125	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. <i>European Journal of Haematology</i> , 2016, 97, 342-347.	2.2	9
126	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2159-2164.	2.0	26



#	ARTICLE	IF	CITATIONS
127	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016, 122, 3831-3837.	4.1	27
128	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	4.1	16
129	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	4.1	75
130	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	49
131	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
132	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.4	5
133	Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 999-1001.	2.4	7
134	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.4	12
135	Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. <i>Blood Cancer Journal</i> , 2016, 6, e396-e396.	6.2	27
136	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 226-231.	2.0	15
137	Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. <i>Bone Marrow Transplantation</i> , 2016, 51, 307-309.	2.4	3
138	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	1.3	17
139	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. <i>Blood</i> , 2016, 128, 3554-3554.	1.4	4
140	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5884-5884.	1.4	1
141	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2270-2270.	1.4	6
142	WaldenstrÃ¶m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 74.	17.0	15
143	High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. <i>Bone Marrow Transplantation</i> , 2015, 50, 668-672.	2.4	7
144	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 472-476.	0.4	28

#	ARTICLE	IF	CITATIONS
145	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1405-1412.	2.0	22
146	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
147	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
148	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 687-693.	0.4	29
149	Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. <i>Leukemia</i> , 2015, 29, 1945-1948.	7.2	12
150	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1413-1417.	2.0	5
151	Chromosome 8q24.1 c-MYC abnormality: a marker for high-risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 602-607.	1.3	38
152	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 3155-3155.	1.4	9
153	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	1.4	5
154	Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2015, 126, 5390-5390.	1.4	0
155	Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. <i>Bone Marrow Transplantation</i> , 2014, 49, 465-466.	2.4	4
156	The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. <i>British Journal of Cancer</i> , 2014, 111, 628-636.	6.4	69
157	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1183-1189.	2.0	89
158	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
159	Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. <i>Bone Marrow Transplantation</i> , 2014, 49, 1036-1041.	2.4	17
160	Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e151-e155.	0.4	2
161	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 319-326.	0.4	55
162	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.4	21

#	ARTICLE	IF	CITATIONS
163	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. <i>Leukemia Research</i> , 2014, 38, 896-900.	0.8	8
164	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8601-8601.	1.6	0
165	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8538-8538.	1.6	0
166	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1453-1458.	2.0	18
167	Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S234-S235.	2.0	1
168	Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 344-356.	2.0	90
169	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
170	Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. <i>Experimental Hematology</i> , 2013, 41, 719-730.	0.4	14
171	Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization. <i>American Journal of Hematology</i> , 2013, 88, 754-757.	4.1	22
172	Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 625-631.	2.5	22
173	Plasmablastic Lymphoma: 28 Patient Single Institution Experience. <i>Blood</i> , 2013, 122, 4310-4310.	1.4	4
174	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 5356-5356.	1.4	5
175	Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7011-7011.	1.6	3
176	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7010-7010.	1.6	0
177	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). <i>Blood</i> , 2013, 122, 2142-2142.	1.4	0
178	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3358-3358.	1.4	0
179	Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1525-1529.	1.3	26
180	Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 118-122.	1.3	74

#	ARTICLE	IF	CITATIONS
181	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1835-1844.	2.0	227
182	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	27.0	1,024
183	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. <i>Cancer</i> , 2012, 118, 2507-2515.	4.1	39
184	Durable remission with salvage second autotransplants in patients with multiple myeloma. <i>Cancer</i> , 2012, 118, 3549-3555.	4.1	69
185	Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. <i>American Journal of Hematology</i> , 2012, 87, 172-174.	4.1	10
186	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 272-276.	4.1	25
187	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. <i>Blood</i> , 2012, 120, 3094-3094.	1.4	1
188	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. <i>Blood</i> , 2012, 120, 4200-4200.	1.4	5
189	Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2012, 120, 3115-3115.	1.4	1
190	C-MYC Rearrangement: A Marker for High-Risk Myeloma. <i>Blood</i> , 2012, 120, 4989-4989.	1.4	0
191	Acquired Therapy-Related Cytogenetic Clones in Patients Treated for Multiple Myeloma. <i>Blood</i> , 2012, 120, 4059-4059.	1.4	0
192	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 3129-3129.	1.4	1
193	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	10.7	263
194	Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 510-515.	2.4	22
195	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2011, 118, 333-333.	1.4	1
196	A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 4108-4108.	1.4	0
197	Determinants of Higher Pre-Apheresis CD34+ Count in Patients Undergoing Autologous Hematopoietic Stem Cell Mobilization. <i>Blood</i> , 2011, 118, 4387-4387.	1.4	0
198	A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. <i>Blood</i> , 2011, 118, 4156-4156.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Nonmyeloablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. <i>Blood</i> , 2011, 118, 894-894.	1.4	2
200	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. <i>Blood</i> , 2011, 118, 2006-2006.	1.4	0
201	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. <i>Blood</i> , 2011, 118, 4118-4118.	1.4	4
202	The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. <i>American Journal of Hematology</i> , 2010, 85, 502-504.	4.1	8
203	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. <i>Blood</i> , 2010, 116, 3510-3510.	1.4	0
204	Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 718-723.	2.0	150
205	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 812-816.	2.0	68
206	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1265-1270.	2.0	37
207	Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S261-S265.	1.4	11
208	Stem Cell Transplantation with 90Yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. <i>Blood</i> , 2009, 114, 868-868.	1.4	2
209	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). <i>Blood</i> , 2009, 114, 2310-2310.	1.4	1
210	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). <i>Blood</i> , 2009, 114, 3213-3213.	1.4	0
211	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. <i>Blood</i> , 2009, 114, 2309-2309.	1.4	0
212	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 4354-4354.	1.4	1
213	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. <i>Blood</i> , 2009, 114, 1227-1227.	1.4	0
214	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1401-1407.	2.0	39
215	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. <i>Blood</i> , 2008, 112, 3320-3320.	1.4	2
216	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. <i>Blood</i> , 2008, 112, 1128-1128.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.. Blood, 2008, 112, 1142-1142.	1.4	0
218	High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood, 2008, 112, 4452-4452.	1.4	2
219	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood, 2008, 112, 3298-3298.	1.4	0
220	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood, 2008, 112, 2999-2999.	1.4	1
221	Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood, 2008, 112, 3306-3306.	1.4	0
222	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 4326-4326.	1.4	0
223	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood, 2008, 112, 3297-3297.	1.4	0
224	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood, 2008, 112, 799-799.	1.4	0
225	Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood, 2007, 109, 2751-2758.	1.4	98
226	Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan. Biology of Blood and Marrow Transplantation, 2007, 13, 454-462.	2.0	117
227	Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with <sup>166</sup> Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. Biology of Blood and Marrow Transplantation, 2007, 13, 543-549.	2.0	29
228	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biology of Blood and Marrow Transplantation, 2007, 13, 1066-1072.	2.0	40
229	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplantation, 2007, 39, 279-283.	2.4	41
230	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. Blood, 2007, 110, 283-283.	1.4	9
231	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. Blood, 2007, 110, 577-577.	1.4	5
232	Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).. Blood, 2007, 110, 948-948.	1.4	3
233	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. Blood, 2007, 110, 5126-5126.	1.4	0
234	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs).. Blood, 2007, 110, 1900-1900.	1.4	0

#	ARTICLE	IF	CITATIONS
235	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. Blood, 2007, 110, 3032-3032.	1.4	1
236	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	1.4	0
237	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood, 2007, 110, 5015-5015.	1.4	0
238	Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1360-1364.	1.3	7
239	Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. British Journal of Haematology, 2006, 133, 533-537.	2.5	47
240	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 2006, 106, 1084-1089.	4.1	69
241	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2006, 108, 3090-3090.	1.4	1
242	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. Blood, 2006, 108, 315-315.	1.4	14
243	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. Blood, 2006, 108, 3668-3668.	1.4	5
244	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin's Lymphoma (NHL) in Patients over 65 Years of Age.. Blood, 2006, 108, 3059-3059.	1.4	0
245	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. Blood, 2006, 108, 5422-5422.	1.4	0
246	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. Blood, 2006, 108, 3101-3101.	1.4	0
247	Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. American Journal of Hematology, 2005, 80, 43-45.	4.1	22
248	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2005, 106, 1159-1159.	1.4	3
249	The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 1803-1803.	1.4	0
250	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. Blood, 2005, 106, 2923-2923.	1.4	1
251	Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 1135-1135.	1.4	6
252	Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 703-713.	2.2	8

#	ARTICLE	IF	CITATIONS
253	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.. Blood, 2004, 104, 259-259.	1.4	47

254 Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for